







FOCUS


Future of Care in Understanding Steatohepatitis

MASLD

 **Concorde El Salam
Hotel Cairo**
Track location 

 **10&11 | JUL | 2025**
Add to your calendar 

 **Registration**
Tab to register 



Organized by

EVA PHARMA

FOCUS

Future of Care in Understanding Steatohepatitis

MASLD

A Historic Milestone for the Middle East
For the first time ever, the




European Association for the Study of the Liver (EASL) endorses an educational liver disease program in the **Middle East**.

FOCUS - SLD Middle East School of Hepatology

is now **globally recognized for excellence** in MASLD education. **A proud moment for the region. A new era in hepatology.**

In collaboration between:




UCHID
United Conference of
Hepatogastroenterology
and infectious Diseases



SASLT
الجمعية السعودية لأمراض وزراعة الكبد
Saudi Society for the Study of Liver Disease
and Transplantation



Proudly Sponsored by



EVA PHARMA



FOCUS - Middle East School of Steatotic Liver Disease (SLD)

We are pleased to invite you to participate in the **Middle East School of Steatotic Liver Disease**, a dedicated educational initiative focused on **MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)** and fatty liver disease.

Program Overview

This scientific program is designed to support hepatogastroenterologists across the Middle East, with the aim of addressing the increasing burden of liver diseases.

In **2025**, the curriculum will feature a comprehensive SLD module that integrates the latest global research, evolving disease nomenclature, and current best practices in diagnosis, management, and prevention.

Program Format

The training will be delivered across three structured waves, ensuring progressive learning and continuous engagement:

Module 1: Pathophysiology, Epidemiology & Diagnosis Foundations

Module 2: MASLD Risk Assessment & Therapeutic Interventions

Module 3: MASLD Cirrhosis, Multidisciplinary Care & Public Health Integration

Key Benefits for Participants

- Stay updated on the most common chronic liver disease worldwide (**MASLD**) whose prevalence continues to rise
- Gain hands-on knowledge to enhance your clinical practice
- Network with peers and regional & International experts in hepatology

10&11 | **JUL** | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

UCHID ADVISORY BOARD



Gamal Esmat



Imam Waked



Maysaa Abdallah

COURSE CO-ORDINATORS



Ahmed Cordie



Faisal Abalkhail



Fatma Elrashdy



Sven Francque

ORGANIZING TEAM



Ibrahim Amer



Abdullah Elhakim



Sara Khaled



Thyab Al Thyab

10&11 | JUL | 2025

Organized by





FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

INTERNATIONAL SPEAKERS



Kate Hallsworth



Luca Miele



Manuel Romero Gomez



Matthias Mandorfer



Mohamed Alghamdi



Raluca Pais



Sven Francque

10&11 | JUL | 2025

Organized by





Endorsed



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

COMMITTEE

NATIONAL FACULTY



Ahmed Tageldien



Ali Ibrahim



Ashraf El Bereedy



Ashraf Omar



Ehab Salem



Eman Barakat



Fahim Basiony



Heba Ismail



Hosam Abdel-Aziz



Magdy Abdelhamid



Merna Marwan



Mohammed Amin



Mona Amin



Mona Hegazy



Noha Sabry



Salma Omran




Wael Tobar



Zeinab Hefny

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis

MASLD


DAY 1

Part1

Time	Lecture	Speakers	Panelists
02:00 - 03:00 PM	Lunch & Registration		
03:00 - 03:30 PM	Diagnosis of clinically significant portal hypertension in SLD Discussion	Matthias Mandorfer	
03:30 - 04:00 PM	Case discussion: Screening for HCC in SLD patients Discussion	Ahmed Cordie Salma Omran	Ahmed Tageldien Ali Ibrahim Ashraf Omar
04:00 - 04:30 PM	Beyond the Liver: NAFLD and CVD Discussion	Magdy Abdelhamid	Ibrahim Amer Mohammed Alghamdi
04:30 - 05:00 PM	Goals of management: terminology and definitions Discussion	Sven Francque	
05:00 - 05:30 PM	Obesity and its relation to MASLD Discussion	(TBC)	
05:30 - 06:00 PM	Coffee Break		

10&11 | JUL | 2025





FOCUS

Future of Care in Understanding Steatohepatitis MASLD

DAY 1

Part2

Time	Lecture	Speakers	Panelists
06:00 - 06:30 PM	Weight management: the ultimate goal in MASLD? Discussion	Sven Francque	
06:30 - 07:00 PM	Dietary Management of SLD patients Discussion	Zeinab Hefny	Eman Barakat Maysaa Abdallah Merna Marwan
07:00 - 07:30 PM	Physical Activity, Exercise & MASLD:How can we support patients to increase their activity levels? Discussion	Kate Hallsworth	Mohammed Alghamdi Mohammed Amin Mona Hegazy
07:30 - 08:00 PM	Lifestyle modifications other than diet and exercise Discussion	Luca Miele	
08:00 - 09:00 PM	Dinner (Meet The Mentor)		

10&11 | JUL | 2025





FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Matthias Mandorfer

Dr. Mandorfer studied Medicine in Vienna & Heidelberg and obtained his M.D. degree in 2012.

He is a consultant in Internal Medicine (since 2018) and Gastroenterology and Hepatology (since 2021) and currently in training for Intensive Care. In 2019, he stayed as a fellow at the Barcelona Hepatic Hemodynamic Lab, Liver Unit, Hospital Clínic.

Dr. Mandorfer obtained his Ph.D. degree in 2017 and a junior faculty position in 2018. Since 2021, Dr. Mandorfer is a senior faculty member (Ap.Prof.; Medical University of Vienna) at the Division of Gastroenterology and Hepatology, Medical University of Vienna, and has been appointed head of the Vienna Hepatic Hemodynamic Lab.

He serves as an associate editor of JHEP Rep and is/was a member of the editorial boards of Gastroenterology, J Hepatol, Hepatology, Am J Gastroenterol, and Liver Int.

He is part of the Baveno Cooperation Steering and Research Committees and also serves as treasurer. In addition, he contributes to EASL (YI Task Force), UEG (National Society Forum), and EF-CLIF (Inspiring and Writing Group).

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Sven Francque

Prof. Sven Francque is a leading expert in gastroenterology and hepatology, with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and portal hypertension as key expertise.

He earned his MD from the University of Antwerp and completed training in Belgium and France.


Prof. Francque received his PhD in 2011, focusing on vascular changes in steatosis.

He has authored over 300 papers and book chapters and served as an editor for JHep Reports. Currently, he is the chairman of the Department of Gastroenterology and Hepatology at the University Hospital Antwerp and a senior full professor at the University of Antwerp.

He is also a key figure in Belgian gastroenterology, coordinating national MASLD guidelines and the Belgian Week of Gastroenterology. He is member of the EASL Governing Board as educational councilor.

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Mohamed Alghamdi

Dr. Mohammed Y. Alghamdi, MD, FRCPC, is a consultant in internal medicine, gastroenterology, hepatology, and liver transplantation.

He has served as the past president of the Saudi Association for the Study of Liver Diseases and Transplantation (SASLT) and the GI Scientific Committee at the Saudi Commission for Health Specialties.


Currently, he is the Executive Director of Training at the Saudi Council for Health Specialties and Chief of Physicians at the King Fahd Military Complex in Dhahran, Saudi Arabia.

Dr. Mohamed Y. Alghamdi holds board certifications in internal medicine and gastroenterology from both the American and Canadian boards.

He completed his fellowship in Hepatology and Liver Transplantation at the University of Western Ontario, Canada.

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD

DAY

2

Time	Lecture	Speakers	Panelists
10:00 - 10:30 AM	Day 1 Recap	Ahmed Cordie Salma Omran	
10:30 - 11:00 AM	Psychological support for SLD patients Discussion	Noha Sabry	Ashraf El Bereedy Ehab Salem
11:00 - 11:30 AM	Anti-diabetes medications Discussion	Mona Amin	Hosam Abdel-Aziz Imam Waked
11:30 - 12:00 PM	Other medications to be used in SLD patients Discussion	Manuel Romero-Gomez	
12:00 - 01:00 PM	Workshop: Practical demonstration of HCC management	Heba Ismail Ibrahim Amer	Ashraf El Breedy
01:00 - 02:00 PM	Prayer Time & Coffee Break		
02:00 - 02:30 PM	State of art lecture: Microbiota and MASLD	Gamal Esmat	
02:30 - 02:50 PM	Resmetirom and other thyroid hormonereceptor agonists for SLD	Raluca Pais	Gamal Esmat Mona Amin Wael Tobar
02:50 - 03:20 PM	Possible future treatments: Drugs in phase 2 and 3 trials Discussion	Sven Francque	
03:20 - 03:40 PM	Role of bariatric surgery in SLD patients	Fahim Basiony	
03:40 - 04:40 PM	Lunch (Meet The Mentor)		
04:40 - 06:40 PM	Expert case scenarios discussion	Fatma Elrashdy	Maysaa Abdallah Sven Francque

10&11 | JUL | 2025

Organized by





FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Kate Hallsworth

Dr. Kate Hallsworth is a Consultant AHP and Clinical Academic Physiotherapist at the Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH), UK, and a NIHR Senior Clinical and Practitioner Research Awardee (SCPRA). She completed her PhD at Newcastle University on physical activity and exercise in MASLD and has published leading research on lifestyle management in long-term conditions.

Her work focuses on overcoming barriers to implementing lifestyle interventions in clinical practice and developing tools to support healthcare professionals. She led the creation of a MASLD-specific digital intervention, co-designed with patients and piloted in the NHS.

Clinically, she leads an AHP-led structured group education programme for MASLD within one of the UK's largest services. She also co-led the Active Hospitals Pilot and promotes non-pharmacological self-management for chronic conditions.

Dr. Hallsworth is a member of the EASL Nurse and AHP Taskforce and the BASL AHP Committee, and has contributed to EASL MASLD Patient Guidelines and international statements from ACSM and ESSA. In 2021, she received the EASL Rising Star Award for her person-centred work in liver disease.

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Luca Miele

- Head of the Liver Transplant Pre-Clinical Unit, affiliated with the Internal Medicine and Liver Transplant Ward, 2022-current.
- Head of the Day Hospital for Liver Transplant Medicine and of the Outpatient Clinics for liver pre-transplant medicine and for Steatotic Liver Disease, 2022-current.
- Medical Officer at Policlinico Gemelli Hospital since 2008.
- Honorary Consultant in Internal and Liver Medicine at the NAFLD Clinic and Liver Transplant Center, Freeman Hospital, Newcastle upon Tyne, UK, 2006–2007.
- Research Associate at Newcastle University (UK), 2006–2007.
- EASL Sheila Sherlock Fellowship at Newcastle University (UK), 2006–2007.
- Italian Board of Physicians, Surgeons and Orthodontists registration, District of Rome: 51227 (since 2001).
- Italian Scientific Habilitation as Full Professor of Internal Medicine and Gastroenterology.
- Academic position as Tenure-Track Ass. Professor in Internal Medicine, Catholic University of the Sacred Heart.

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Manuel Romero Gomez

Prof. Dr. Manuel Romero-Gómez is Director of UCM Digestive Diseases at Virgen del Rocío University Hospital, Full Professor at the University of Seville, and leads the SeLiver Group at IBIS.

He is PI at Ciberehd and CTS-532 research groups, and directs the Hepatic, Digestive, and Inflammatory Diseases Translational Research Program.


He serves as an external expert for multiple organizations, including ISCIII and the European Commission, and leads several European projects, including LITMUS and GRIP-on-NASH.

President of AEEH (2023-2025), he coordinated the Covid-19 Personalized Medicine group in Andalusia.

Awarded the Fama Prize (2024), he holds 10+ patents and has published over 555 papers (H-Index 93, Scopus 2025). He enjoys liver research, family time, biking, and running.

10&11 | JUL | 2025

Organized by



EVA PHARMA



FOCUS

Future of Care in Understanding Steatohepatitis MASLD



Raluca Pais


Dr Raluca Pais is MD PhD in Hepatogastroenterology Department and Institute of Cardiometabolism and Nutrition, Pitié Salpêtrière Hospital, Paris, France.

She first completed her medical training at University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, Romania.

She earned her doctoral degree at the University Pierre et Marie Curie, Paris VI for her work on the natural history and progression of non-alcoholic fatty liver disease, liver and cardiovascular related comorbidities related to NAFLD.

10&11 | **JUL** | 2025

Organized by



EVA PHARMA



GROUP 1

Mentor

Mina Tharwat

Aswan
University

Name

Sara Salah
Nehal Abdeldayem
Madona Magdy
Nasser Alamer
Bavly Ashraf

University

Zagazig University
Aswan University
Tanta University
KSA
Cairo University

GROUP 2

Mentor

Ahmed Kamal

Alex
University

Name

Amira Al-Sadek
Hania Abdellatif
Mina Adel
Ibrahim Sulaiman
Elham Salah

University

Zagazig University
Assuit University
Cairo University
KSA
Aswan University

GROUP 3

Mentor

Ammar Abdelghani

Cairo
University

Name


Mostafa El-Ateek
Nesrin Mohamed
Eslam Mohamed
Reem Ali
Asem Osama
Mirna Atef

University

Benha University
Alex University
Kafr Elshiekh University
Cairo University
KSA
Cairo University

10&11 | JUL | 2025

Organized by



EVA PHARMA



GROUP 4

Mentor

Al-Zahraa Mohamed

Beni Suif
University

Name

Ahmed Sayed

Omnia Ahmed

Heba Ashraf

Omar Aboulhamayed

Noura Gamal

University

Benha University

Portsaid University

Menofia University

Cairo University

Liver Institute

GROUP 5

Mentor

Fatma El-Rashdy

Cairo
University

Name

Dalia Elsayed

Sara Ashraf

Ahmed El Saieed

Andrew A.Saweres

Badr Al Dahsh

Fady Raouf Shafik

University

Mansoura University

Portsaid University

Kafr Elshiekh University

Cairo University

KSA

Liver Institute

GROUP 6

Mentor

Mahmoud El-Kerdawy

Kafr Elshiekh
University

Name

Christina Samir

Manar Metwalli

Nasser Alhowaish

Nehad Darwesh

Sarah Yasser Mira

University

Alex University

Mansoura University

KSA

Liver Institute

Cairo University

10&11 | **JUL** | 2025

Organized by



EVA PHARMA